NCT01407406View on ClinicalTrials.gov

Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Healthy Volunteers
Interventions
DRUG

BIIB023 - low dose IV Dose

DRUG

BIIB023 - high dose IV Dose

Trial Locations (2)

Unknown

Research Site, Melbourne

Research Site, Hong Kong

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT01407406 - Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers | Biotech Hunter | Biotech Hunter